VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

PROSCA BLADDR 2021 | Is ADT alone for patients with mHSPC appropriate?

Robert Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, outlines whether there are patients with metastatic hormone-sensitive prostate cancer (mHSPC) where treatment with androgen deprivation therapy (ADT) alone is appropriate, as discussed at the APCCC 2021 consensus meeting. This interview took place at the PROSCA/BLADDR 2021 congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter